Macitentan to Prevent PRVO
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- 1 May 2024
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Macitentan 10mg
- Record updated
- 8 March 2024
- Why it stopped
- Study was cancelled by funding agency before starting enrollment.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (18)Hide the full registry criteria
Who can take part
- Age 18-75 years old
- Acute high-risk or intermediate-risk PE diagnosed by CTPA within 28 days prior to enrollment
Who cannot take part
- Surgical interventions to treat PE including catheter-directed thrombolysis, catheter-based thrombectomy, or surgical pulmonary embolectomy
- History of pulmonary embolism prior to index PE
- Current or previous use within 90 days of an endothelin-receptor antagonist, prostacyclin analogue, phosphodiesterase type 5 inhibitor, or nitric oxide donor
- Subjects receiving CYP3A4 and CYP2C9 inhibitors or inducers such as rifampin, ritonavir, fluconazole, amiodarone
- Allergy or contraindications to Macitentan or any other endothelin receptor antagonist
- History of pulmonary hypertension including Group 1 (Primary pulmonary hypertension), Group 2 (secondary to left heart disease), Group 3 (secondary to lung disease), Group 4 (Chronic thromboembolic pulmonary hypertension)
- Severe chronic obstructive pulmonary disease
- History of radiation therapy to the chest
- Severe allergic reaction to iodine contrast
- Contraindication for anticoagulation
- Known inherited or acquired hypercoagulable states
- Severe uncontrolled asthma
- Pregnancy or fertility treatment
- Breastfeeding
- Life expectancy is less than 6 months
- Not able to read or understand the English language
Where in United States
- University of Maryland Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
About half of patients who suffer of a pulmonary embolism (blood clots in the lungs), do not clear completely the clots overtime, increasing the risk of having a new blood clot in the lungs and elevated blood pressure in the pulmonary artery; therefore, developing fatigue, shortness of breath, and heart failure.
Read full original descriptionShow less
The objective of this clinical trial is to compare 3 months of daily Macitentan (a medicine to increase the diameter of the pulmonary artery) in addition to blood thinners vs. blood thinners alone in patients with acute blood clots in the pulmonary artery:
Question 1: Whether the use of Macitentan in addition to blood thinners enhances the process of cleaning the blood clot in the pulmonary artery compared to blood thinners alone.
Question 2: Whether the use of Macitentan in addition to blood thinners is associated to improve the fatigue and shortness of breath in patients after a pulmonary embolism compared to blood thinners alone.
Participants will be asked to take a capsule for 3 months in addition to blood thinners. The capsule could contain either Macitentan (medicine) or a placebo (not medicine). In 3 months, participants will have a new image of the pulmonary artery to document the cleaning of the clots. Also, blood and urine samples will be collected, as well as a questionnaire will be filled out. In 6 months, patients will have repeated images of the heart as well as repeated questionnaires.
The 2 groups in the trial
- Macitentan armTreatment being tested
Participants allocated to this arm will receive Macitentan 10 mg daily for 3 months
Treatment: Macitentan 10mg
- PlaceboPlacebo, for comparison
Participants allocated to this arm will receive placebo daily for 3 months.
Treatment: Macitentan 10mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of MACitentan on the Prevention of Residual Pulmonary vasculaR Occlusion
- Record updated
- 8 March 2024